A mismatched dosage unit or an inconsistent MedDRA Preferred Term can turn a solid regulatory submission into a linguistic review finding—or, in the worst cases, a patient safety event. Across the EU, US, and other major markets, pharmaceutical product information must meet exacting standards that go well beyond fluent language. Translators and regulatory teams work under tight constraints set by the European Medicines Agency’s Quality Review of Documents (QRD) templates and the Medical Dictionary for Regulatory Activities (MedDRA). These frameworks leave little room for stylistic preference or approximate wording.
The QRD templates dictate the structure, mandatory headings, and many fixed phrases for the Summary of Product Characteristics (SmPC), package leaflet, and labelling. Version 10.4 remains the current published standard for most submissions, with version 11 having undergone public consultation focused on improving package-leaflet clarity and length. Every official EU language version, plus Icelandic and Norwegian, must track the approved English master text line by line. Standard statements cannot be reworded; Member State “blue-box” requirements and national preferences add further layers. Decimal formatting, number grouping, and certain abbreviations follow language-specific conventions. A translation that reads naturally yet ignores these conventions is still non-compliant. Template updates must be applied simultaneously across all language versions. Failure to do so routinely triggers comments during the linguistic review that compress correction windows and risk delaying Day 215–Day 235 milestones.
MedDRA sits at the centre of the most safety-critical sections. Section 4.8 of the SmPC (Undesirable effects) relies on MedDRA Preferred Terms. The dictionary is hierarchical, multiaxial, and maintained under ICH oversight in multiple languages. The same numeric code maps equivalent terms across languages, supporting interoperability between industry databases and regulators. Translators and reviewers therefore work from the official MedDRA release relevant to the submission rather than general medical dictionaries or ad-hoc glossaries. Using an unofficial synonym—even one that feels more natural—breaks that mapping. It can reclassify severity, obscure signal detection, or create discrepancies between the SmPC, package leaflet, and pharmacovigilance systems. Recent work on MedDRA Labelling Groupings aims to cluster near-synonymous terms so that clinically related reactions are not scattered, but until broader standardisation takes hold, sponsors and language partners still manage consistency product by product and language by language.
Dosage units and contraindications present equally high-stakes challenges. Documented cases show how everyday language traps become medical errors. The English instruction “take once daily” left untranslated or poorly handled on bilingual Spanish labels has been read by patients as “eleven times a day” because “once” is the Spanish word for eleven. Confusions between µg and mg, mL and L, or household measures and metric volumes have produced overdoses and under-doses. Analyses of FDA drug-recall data from 2012–2023 attribute roughly 19 percent of recalls to labelling or packaging issues; a separate look at 2017–2019 recalls put labelling errors at about 15 percent of the total. On the patient side, studies of computer-generated Spanish prescription labels have shown error rates approaching 50 percent in some pharmacy settings. Similar patterns appear in other languages when dosage instructions, route of administration, or contraindications drift even slightly from the source.
These failures are rarely the result of careless freelancers. They arise when projects lack a locked termbase built from MedDRA Preferred Terms and QRD-approved phrases, when review cycles skip native-speaking medical reviewers, or when machine output is treated as final rather than as a draft requiring specialist post-editing. Effective programmes treat terminology as a controlled asset. Teams maintain client- and product-specific glossaries aligned with the latest MedDRA release and QRD style decisions. They apply version control so that a late English amendment propagates correctly to every language. Native medical reviewers check not only linguistic accuracy but also clinical sense and national terminology preferences. Numerical validation is treated as a distinct step, because a misplaced decimal or unit abbreviation can escape ordinary linguistic review.
The same discipline applies beyond the EU. FDA labelling requirements, Health Canada standards, and requirements in Japan, Australia, and other ICH regions all demand consistent terminology and precise unit handling. Global companies that treat translation as a late-stage administrative task repeatedly rediscover the cost of that approach. Those that integrate controlled terminology management and regulatory-aware review into the workflow from the outset submit cleaner files, face fewer linguistic findings, and reduce the risk of post-approval corrections that can force variations or, in extreme cases, recalls.
Artlangs Translation has spent more than two decades supporting pharmaceutical and life-science clients with precisely this level of discipline. The company works across 230-plus languages with a network of more than 20,000 professional linguists and subject-matter specialists. Its teams handle QRD-compliant product information, MedDRA-aligned adverse-event sections, and full labelling packages for markets worldwide, alongside broader services that include video localization, short-drama subtitle localization, game localization, multilingual dubbing for short dramas and audiobooks, and multilingual data annotation and transcription. The combination of regulatory familiarity, terminology control, and scale allows sponsors to keep multilingual labelling aligned with both scientific accuracy and the letter of current templates.
